Preliminary studies suggest that quetiapine, a mixed dopaminergic and serotonergic agent used for the treatment of psychosis, may decrease substance use in patients with schizophrenia.
Quetiapine may have a positive impact on alcohol use in patients with co-occurring schizophrenia/schizoaffective disorder and alcohol use disorder. Randomized, controlled trials are needed to clarify whether quetiapine has a specific effect on alcohol use in patients with such co-occurring disorders.
Read Full Abstract
Request Reprint E-Mail: Mary.f.brunette@dartmouth.edu __________________________________________